Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients

Fig. 1

The survival curves of HCC patients receiving anti-PD-1 immunotherapy. Patients with AFP reduction> 50% has significantly longer progression-free survival (PFS) than those with AFP reduction≤50% (A). Similarly, patients with PIVKA-II reduction > 50% also had better PFS (B). The PFS of HCC patients with AAP score ≥ 2 was significantly improved than those with AAP score ≤ 1 (C). In terms of overall survival (OS), patients with AFP reduction> 50% has significantly improved OS compared to those without (D). The OS of patients with PIVKA-II reduction > 50% was significantly longer (E). Patients with AAP score ≤ 1 had worse OS compared to those with AAP score ≥ 2 (F)

Back to article page